Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Neuromuscular and peripheral nerve disorders

Burden of disease in myasthenia gravis: taking the patient's perspective.

Sophie Lehnerer; Jonas Jacobi; Ralph Schilling; Ulrike Grittner; Derin Marbin; Lea Gerischer; Frauke Stascheit; Maike Krause; Sarah Hoffmann; Andreas Meisel

Originally published in Journal of neurology · 2021-11-20

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Background Myasthenia gravis (MG) leads to exertion-dependent muscle weakness, but also psychological and social well-being are limited. We aim to describe the burden of disease in MG including sociodemographic, economical, psychosocial as well as clinical aspects, to compare health-related quality of life (HRQoL) of patients with MG to the general population (genP) and to explore risk factors for a lower HRQoL. Methods This case-control study was conducted with MG patients of the German Myasthenia Association. A questionnaire-based survey included sociodemographic and clinical data as well as standardized questionnaires, e.g. the Short Form Health (SF-36). HRQoL was compared to genP in a matched-pairs analysis. Participants of the German Health Interview and Examination Survey for Adults (DEGS1) served as control group. Results In our study, 1660 MG patients participated and were compared to 2556 controls from the genP. Patients with MG showed lower levels of physical functioning (SF-36 mean 56.0, SD 30.3) compared to the genP (mean 81.8, SD 22.1, adjusted difference: 25, 95% CI 22-29) and lower mental health sub-score (SF-36 mean 67.3, SD 19.8, vs.

Discussion

In this study, we demonstrate that HRQoL is markedly lower in MG patients compared with the general population (genP). The overall burden is particularly high among women, in high disease severity levels, in low-income groups and among middle-aged and older patients.

Conclusion

Our study emphasizes that the mental and physical health-related quality of life in MG patients is remarkably lower in comparison to the genP. Quality of life reflects one aspect of the burden of disease. Our data demonstrate that many factors are a piece of the puzzle to create a holistic view on the burden of disease. It would make sense to develop a tool that integrates other influencing factors besides quality of life, such as functional level, depression and anxiety, fatigue and social participation.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?